3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Interventions
Carboplatin
14
pembrolizumab
12
Gemcitabine
11
Cisplatin
11
Rituximab
8
durvalumab
7
Pemetrexed
6
Nivolumab
6
osimertinib
5
atezolizumab
5
Specimen Handling
5
Paclitaxel
5
Dexamethasone
5
amivantamab
4
Prednisone
4
Ipilimumab
4
Cyclophosphamide
4
Bortezomib
4
Bendamustine Hydrochloride
4
tremelimumab
3
trastuzumab deruxtecan
3
olaparib
3
niraparib
3
lazertinib
3
entrectinib
3
enfortumab vedotin
3
daratumumab
3
belzutifan
3
alectinib
3
acalabrutinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Cobicistat
×
90 days
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA